-1,3-Glucans from fungi and yeasts 1, 2) have been reported to show anti-tumor activities through stimulating host immune responses such as macrophages, natural killer cells, and cytotoxic T lymphocytes. Meanwhile, only a few reports have been published about the antitumor activities of -glucans, though structurally diverse -glucans are widely distributed in natural biological resources, including plants, animals, and microorganisms.
3) For example, it has been reported that a proteinbound -glucan extracted from mycelia of Tricholoma matsutake shows anti-tumor and immune-enhancing activities, although its purified -glucan does not show such activities. 4) In fact, the immune-stimulating activity of a polysaccharide fraction purified from Agaricus blazei likely depends on its major active principle, -1,4 glucan-linked -1,6 glucan. The fraction, however, is proteoglycan because it is not free of protein. 5) Recently, protein-bound -1,3-glucan fractions from Phellinus linteusmycelia have been reported to have anti-tumor activity, 6) Glycogen (-1,6 branched -1,4 glucan) from clams has been reported to have anti-tumor activity, although the activity is dependent upon the extraction methods. 7) Thus the active principles for biological activities of such -glucan preparations have not necessarily been clarified. Further, the molecular weight and anti-tumor activity of glucans are totally dependent upon their sources and the extraction method. 1, 4, 7) These reports imply that an application of synthetic glucans rather than extracted ones is a fundamental necessity to understand their biological activities. In this context, as far as we know, there are only two papers 8, 9) in which enzymatically synthesized -1,6 glucan with branches at C-3 positions has anti-tumor activity.
Recently, methods for synthesizing -1,4:1,6-glucans with controlled structures have been developed. 10) This makes it possible to investigate the relationship between the structure and the biological activities of -glucans. Here we report on the activities of some enzymatically synthesized -1,4:1,6-glucans.
Materials and Methods
Agents. RPMI-1640 and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazorium bromide (MTT) were obtained Preparation of -glucans. Amylose (ESA), a linear -1,4-glucan, was synthesized from sucrose and maltotetraose using the cooperative action of sucrose phosphorylase (SP, EC 2.4.1.7) and -glucan phosphorylase (GP, EC 2.4.1.1). Sucrose was phosphorolyzed to glucose-1-phosphate and fructose by SP in the presence of inorganic phosphate, and the glucosyl moiety of glucose-1-phosphate was transferred to the non-reducing end of maltotetraose by GP librating inorganic phosphate. Thus glucosyl moieties of sucrose molecules were successively transferred to the non-reducing ends of glucan to elongate the chain.
11) SP from Streptococcus mutans 12) and GP from potato were respectively purified from cell extract of E. coli harboring a recombinant plasmid encoding the structural gene for the corresponding enzyme. The detailed procedures for synthesis of ESA and preparations of these enzymes will be described elsewhere (manuscript submitted). Cycloamylose (CA), cyclic -1,4-glucan, was produced from ESA using Thurmus aquaticus amylomaltase, as described previously. 13) Glycogen (ESG) was synthesized from sucrose and maltotetraose using SP, GP, and branching enzyme (BE, EC 2.4.1.18) as follows. A reaction mixture (pH 7) containing 221 mM sucrose, 0.4 mM maltotetraose, 160 mM KH 2 PO 4 , 240 mM Na 2 HPO 4 , 1.6 units/ml GP, 1.6 units/ml SP, and 600 units/ml BE was incubated at 45 C for 16 h with gentle agitation. BE from Aquifex aeolicus was partially purified, as described previously. 14) The mixture was heated at 90 C for 30 min after adjusting pH to 4.5 with HCl to stop the reaction, and then centrifuged. The supernatant was subjected to ultrafiltration (500 kDa molecular mass cut-off membrane module, type FS03-FC-FUS5082, Daisen Membrane Systems Ltd., Tokyo, Japan) to remove fructose and ions from glycogen. Insoluble materials were again removed by centrifugation, and the glycogen was lyophilized. Highly branched cyclic dextrin (HBCD) was prepared from amylopectin using Bacillus stearothermophilus BE, as described previously. 15) Partially degraded amylopectin (AP) was also prepared using BE.
-Amylase treatment of glycogen (ESG) and highly branched cyclic dextrin (HBCD) was prepared using sweet potato -amylase (Sigma) at pH 4.75 and 37 C for 16 h. The structural parameters of the -glucans are summarized in Table 1 .
Structural analysis of -glucans. Weight-average degree of polymerization (DPw) of -glucans was determined using high-performance size-exclusion chromatography with a multi-angle laser light scattering photometer and a differential refractive index detector (HPSEC-MALLS-RI). 13) Number-average chain lengths (CLn) of branched polymers were calculated by the following equation. Number-average chain length = [Total sugars as glucose] Â 100/[non-reducing end residues]. Non-reducing end residues and total sugars were quantified as described previously.
16)
Susceptibility of -glucans to -amylase. Amylase treatment was performed at 37 C for 30 min in 4.5 ml of 10 mM sodium phosphate buffer (pH 7) containing 1% (w/v) -glucans and 0-1.67 units/ml -amylase (from human saliva, Sigma). To investigate the effect of complete digestion, the amount of -amylase and the reaction period were increased to 2 units/ml and 24 h respectively. After boiling of the reaction mixture for 10 min, the reducing sugars were determined by dinitrosalicylic acid methods. The degradation ratio was calculated from the contents of the reducing sugars as glucose per total sugars. The molecular masses of the products were determined with HPSEC-MALLS-RI.
Cell lines and culture conditions. J774.1 and Meth A tumor cells were maintained in a humidified 5-7% CO 2 atmosphere at 37 C and passaged every 4 d. The culture medium was RPMI-1640 containing 5% FBS and gentamicin sulfate (10 g/ml).
Mice and in vivo anti-tumor experiment. BALB/c mice were obtained from Charles River Japan Inc. (Kanagawa, Japan) or from our own colony, and used in the experiments at 7-10 weeks of age.
Anti-tumor experiments of synthesized glucans were carried out in two ways. First, a tumor cell suspension (5 Â 10 6 cells/ml) was mixed with an equal volume of glucan solution (1 mg/ml) or LPS (20 g/ml), and 0.2 ml of the mixture was injected subcutaneously into the backs of the mice (10 mice/group). Secondly, 5 Â 10 5 Meth A cells were injected subcutaneously into the backs of the mice (12-19 mice/group). The mice were freely given a synthesized glucan (ESG) in drinking water 2 d after tumor implantation to the end of the experiments. The experiments were finished at 100 d after tumor implantation and the surviving mice did not carry any tumors. For assessment of TNF-in mouse serum, serum was obtained by bleeding chloroformanesthetized mice by heart punctuation at 14 d after tumor implantation, and stored at À85 C until use. All animal experiments in this paper followed the Guidelines for Animal Experimentation of Aomori University.
Determination of NO 2 levels. Nitric oxide (NO) production of J774.1 cells, as measured NO 2 concentration, was determined by Griess reagent as described previously. 17) In brief, J774.1 cells [5 Â 10 5 cells in 0.2 ml in each well of a 96-well flat-bottomed microplate (Greiner)] were cultured with or without agents. After 20-24 h, 0.1 ml culture fluid from each well was withdrawn and mixed with 0.1 ml Griess reagent. The mixtures were incubated for 10 min at room temperature, and the absorbance at 540 nm minus 655 nm of each well was measured with a Bio-RAD model 550. NO 2 concentrations were measured using sodium nitrite as a standard. The viability of J774.1 cells treated as above with various agents was determined by reduction of MTT, as described previously. 18) The TNF-sensitivity of each tumor cell was measured as follows. Tumor cells (5 Â 10 4 =0:2 ml) in each well of a 96-well flat-bottomed microplate (Greiner) were cultured with or without TNF-at 37 C for 1-3 d. Viable cells were determined by standard MTT assay.
Data presentation and statistical analysis. All experiments were repeated two to five times with similar results. The statistical significance of differences between groups was determined as described previously. 19) Survival curves and statistical analysis were obtained by the Kaplan-Meier method.
Results
Anti-tumor activity of -glucans First, we examined the anti-tumor activity ofglucans. Tumor cells were mixed with each glucan and then the mixture was subcutaneously implanted into the backs of BALB/c mice. Figure 1 shows survival curves of Meth A tumor cells (BALB/c mouse-derived fibrosarcoma cells) (A) and of J774.1 tumor cells (BALB/c mouse-derived macrophage-like cells) (B). In the case of Meth A, ESG was the most effective at inhibiting its growth, ESG was second, and others such as LPS, HBCD, CA, and HBCD were less effective than ESG or ESG. But these glucans were totally ineffective against the growth of J774.1 tumor cells.
Effect of -glucans on nitric oxide production Since the -glucans tested had anti-tumor activity, and various -and -glucans appear to stimulate macrophages, resulting in enhanced accessory activity, augmented NO production, and so on, 1, 2, 5, 20) we examined the effect of various synthesized -glucans on the NO production activity of a macrophage cell line, J774.1 cells. Figure 2 shows two independent experiments in which LPS as a positive control markedly augmented NO production in combination with IFN-but not alone (data not shown). ESG and AP augmented the activity as well. Other -glucans such as CA, HBCD, HBCD, and ESA were almost ineffective. Further, two -glucans purified from oyster (OYG/Nac and OYG/ICN) and pullulan (PUL) were also ineffective.
Effect of -glucans on TNF-production Next we examined the effect of the glucans on TNFproduction by J774.1 cells. LPS markedly augmented production of TNF-, and this augmentation was not dependent on the presence of IFN- (Fig. 3) . ESG and AP also augmented production of TNF-, and the effect of ESG was superior to that of AP.
The macrophage-stimulating activities of ESG and AP were not due to LPS contaminated in the samples because of their quite low amounts of endotoxin ( Table 1) .
Sensitivity of both tumor cells to nitric oxide and TNF-
Since the anti-tumor activity of ESG against Meth A but not J774.1 tumor cells was the most potent among the tested -glucans (Fig. 1) , and ESG most effectively augmented NO and TNF-production (Figs. 2 and 3 ), to Mixtures of 5 Â 10 5 Meth A (A) or J774.1 (B) tumor cells and 500 g of each -glucan or 10 g LPS in a total volume of 0.2 ml were injected subcutaneously into the backs of BALB/c mice. Each group consisted of 10 mice. Thereafter, survival times of the mice were measured. In A, the statistical significances of ESG and ESG, LPS, and CA, and HBCD against Control were P < 0:001, <0:005 and <0:05 respectively. Five Â 10 5 J774.1 cells were cultured with each -glucan (50 g/ml) or LPS (0.5 g/ml) in the presence of IFN-(100 U/ml). After 20-24 h, the culture fluid was withdrawn, and the amounts of nitrite (a product of NO) in the fluid were determined as described in ''Materials and Methods''. The letter above each column indicates the results of the statistical analysis, and the P value for each letter was <0:05. Experiments 1 and 2 are two independent experiments. Fig. 3 . Effects of Synthesized -Glucans on TNF-Production.
Five Â 10 5 J774.1 cells were cultured with each -glucan (50 g/ml) or LPS (0.5 g/ml) in the presence or absence of IFN-(100 U/ml). After 20-24 h, the culture fluid was withdrawn and the amounts of TNF-in the fluid were determined as described in ''Materials and Methods''. The letter above each column indicates the results of the statistical analysis, and the P value for each letter was <0:05.
get some clues as to the anti-tumor activity of ESG against Meth A tumor cells, we examined the sensitivity of both tumor cells to NO and TNF-. Both tumor cells were cultured with a NO-producing agent, NOR4, or TNF-, and then the viability of the tumor cells was measured. Figure 4A shows that J774.1 cells were sensitive to NOR4 in a dose-dependent manner. Meth A tumor cells, however, were not sensitive to the agent at the preset concentrations (data not shown). Meanwhile, Meth A tumor cells were significantly inhibited in their growth by TNF-in a dose-dependent manner, but J774.1 tumor cells were totally resistant to the agent (Fig. 4B) .
Effect of oral administration of ESG on survival of Meth A tumor-bearing mice
The results indicating that ESG potently augmented TNF-production by macrophages and that Meth A tumor cells were quite sensitive to it led us to examine the effect of oral administration of ESG on the survival of Meth A tumor-bearing mice. Figure 5 shows that ESG significantly inhibited Meth A growth at a dose of 50 g/ml in drinking water. A lower dose (5 g/ml) also tended to increase the survival time, but the effect was not significant. Although AP was also a potent macrophage stimulator (Figs. 2 and 3) , it was hard to make a homogeneous solution and we did not examine it against in vivo growth of Meth A tumor cells.
Additionally, as shown in Table 1 , ESG contained under 0.1% protein and 0.014 ppm -glucan. Thus the anti-tumor activity of ESG was not likely to depend on contaminated protein or -glucan.
Susceptibility of -glucans to -amylase
Glycogen is contained in everyday food and may easily be degraded to small fragments by digestive enzymes. To investigate the mechanism of the antitumor activity of ESG by oral administration, the susceptibility of ESG to -amylase was analyzed. Almost the same amounts of reducing sugars were released from ESG and AP after -amylase treatment (Fig. 6A) . About 17 and 16% of the -glucosidic linkages of ESG and AP molecules were hydrolyzed by 1.67 U/ml -amylase, respectively. On the other hand, about 37% of the linkages of OYG/Nac were degraded by the same amounts of -amylase. The high amounts of reducing sugars from OYG/Nac were probably due to its low molecular size (high ratio of surface area to molecular volume). But the decreases in molecular masses of ESG and OYG/Nac were slight compared with the decrease in the mass of AP under the same condition (Fig. 6B) . Even after prolonged incubation with -amylase, macromolecules with an average mass of 2,200 kDa from ESG were detected by HPSEC-MALLS-RI (Table 2) . If the -amylase randomly hydrolyzed linkages of -glucan, the average molecular masses of glucans would rapidly decrease. For example, 10% hydrolysis would result in a product with an average mass of 1,638 Da (average degree of polymerization, 10). Thus these results indicate that -amylase hydrolyzed the only peripheral region of the glycogen molecules. In the case of AP, it is likely that the internal linkages of the molecules were more easily hydrolyzed than those of glycogens. These results suggest the possibility that orally administrated ESG might reach the intestine as macromolecules, leading to effective and lasting immune stimulation.
Discussion
The present study clearly indicates that an enzymatically synthesized -glucan (ESG) significantly stimulated macrophages and prolonged the survival time of Meth A-tumor-bearing mice, and thus resulted in their survival. The glucan was one of the glucose polymers, consisting of a backbone of linear -1,4 glucopyranosyl units with -1,6-linked side chains, and its weightaverage degree of polymerization (DPw) and ratio of branch linkage (BL) were 149,000 and 8.1% respectively. Accordingly partially degraded amylopectin (AP), of which the DPw was 110,000 and the BL was 5.1%, showed potent macrophage-stimulating activity. Kado et al. 8) and Takeda et al. 9) reported the anti-tumor and immunomodulating activities of an almost liner synthesized -1,6-glucan. ESG, however, totally lost its macrophage-stimulating activity by treatment withamylase. Although the DPw of ESG was slightly reduced to 126,000 by the treatment, its BL dramatically increased from 8.1 to 20. Other -glucans, enzymatically synthesized amylose (ESA) with 4,000 DPw and 0% BL, cycloamylose (CA) with 40 DPw and 0% BL, highly branched cyclic dextrin (HBCD) with 1,960 DPw and 5.9% BL, and -amylase-treated HBCD (HBCD) with 1,030 DPw, were ineffective at stimulating macro- BALB/c mice were subcutaneously injected with 5 Â 10 5 Meth A tumor cells, and then were freely given ESG-containing drinking water (5 or 50 g/ml) 2 d after tumor implantation to the end of the experiments. Control, ESG (5 g/ml) and ESG (50 g/ml) groups consisted of 19, 12, and 17 mice respectively. Statistical significance was determined using the Kaplan-Meier method. phages in vitro. In the present study, glycogen from oyster was also ineffective. These results indicate that the anti-tumor and macrophage-activating activities of -glucans are influenced by their polymer sizes, degree of branching, and tertiary structure.
On the other hand, synthesized -glucans did effectively inhibit Meth A tumor growth when they were admixed with the tumor cells and injected subcutaneously into the backs of mice (Fig. 1A) . In this case, ESG was the most effective. ESG, HBCD, CA, and HBCD, however, substantially inhibited growth though they hardly stimulated a macrophage cell line, J774.1 cells (Figs. 2 and 3) . The anti-tumor activity of glucans with insufficient macrophage-activating ability appears to be mediated through a so-called bystander effect. [21] [22] [23] In tumor-growing tissues, inflammation generally takes place and various host cells such as neutrophils, macrophages, natural killer cells, and T cells infiltrate into the sites. Their anti-tumor activities are well regarded, and the degree of their infiltration depends on the immunogenicity of the tumor cells, and on the presence and lasting time of foreign substances such as glucans. Thus it is likely that Meth A tumor cells alone were not enough to stimulate and sustain inflammation in growing sites, and the synthesized glucans tested helped the inflammation. Further, the insufficient macrophageactivating ability of the tested glucans other than ESG might indicate the necessity of some factor(s) for stimulation of macrophages which might be supplied in vivo, since thioglycolate broth-induced mouse peritoneal macrophages become unresponsive to treatment with LPS and IFN-after a certain period (usually 2 d) of in vitro culture without losing viability (unpublished data). It is likely that ESG and AP have their own ability to prime macrophages, but the others (ESG, HBCD, HBCD, CA, OYG, Pul, and ESA) alone may not be enough to prime them fully. This calls for further investigation. ESG, however, was not effective against J774.1 tumor cells. This might be due to their different metastatic abilities. That is, J774.1 cells tended preferentially to metastasize into the liver whereas Meth A tumor cells appeared to have no metastatic potential (manuscript in preparation).
It is reasonable that the anti-tumor activity by oral administration of ESG against Meth A was mediated through intestinal mucosal immunity and that immunostimulators maintaining their effective structure should reach the immunocompetent cells in the intestine. In this context, ESG might be qualified to be an effective immunostimulator, as it was quite resistant to -amylase digestion. Meth A tumor cells were sensitive to TNF-, Fig. 6 . Susceptibility of -Glucans to -Amylase.
Reaction mixtures containing 1% (w/v) -glucans and 0-1.67 units/ml -amylase in 10 mM sodium phosphate buffer (pH 7) were incubated at 37 C for 30 min, and then heated at 100 C for 10 min to stop the reaction. The ratio of hydrolysis (A) was estimated by determination of reducing sugars and total sugars in the reaction mixture. The DPw (B) of hydrolyzates was analyzed using HPSEC-MALLS-RI. The glucans (1% w/v) were treated with 2 U/ml -amylase at pH 7.0 and 37 C for 24 h. Ã2 The glucan with a DPw of <60 could not be detected by this analytical condition.
so that anti-tumor activity by oral administration of ESG might depend on high blood levels of ESG. Its levels, however, were comparable to those without administration of ESG at 14 d after tumor implantation. The mechanisms by which oral administration of ESG mediates anti-tumor activity are now under investigation.
